|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | {{Altest|variable=prueba}} |
| {{Tenecteplase}} | |
| {{CMG}}; {{AE}} {{SS}}
| |
|
| |
|
| {{SB}} TNKASE<sup>®</sup> | | {{{field|Altest|input type=textarea|size=80|editor}}} |
| | |
| ==Overview==
| |
| '''Tenecteplase (TNK)''' is an [[enzyme]] used as a [[thrombolytic drug]].
| |
| | |
| Tenecteplase is a [[tissue plasminogen activator]] (tPA) produced by recombinant DNA technology using an established mammalian cell line (Chinese hamster ovary cells). Tenecteplase is a 527 amino acid glycoprotein developed by introducing the following modifications to the complementary DNA (cDNA) for natural human tPA: a substitution of threonine 103 with asparagine, and a substitution of asparagine 117 with glutamine, both within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296–299 in the protease domain.
| |
| | |
| Tenecteplase is a recombinant fibrin-specific plasminogen activator that is derived from native t-PA by modifications at three sites of the protein structure. It binds to the fibrin component of the thrombus (blood clot) and selectively converts thrombus-bound plasminogen to plasmin, which degrades the fibrin matrix of the thrombus. Tenecteplase has a higher fibrin specificity and greater resistance to inactivation by its endogenous inhibitor (PAI-1) compared to native t-PA.
| |
| | |
| ==Category==
| |
| Cardiovascular Drugs:Thrombolytic drugs
| |
| ==FDA Package Insert==
| |
| | |
| '''| [[Tenecteplase indications and usage|Indications and Usage]]'''
| |
| '''| [[Tenecteplase dosage and administration|Dosage and Administration]]'''
| |
| '''| [[Tenecteplase contraindications|Contraindications]]'''
| |
| '''| [[Tenecteplase warnings and precautions|Warnings and Precautions]]'''
| |
| '''| [[Tenecteplase adverse reactions|Adverse Reactions]]'''
| |
| '''| [[Tenecteplase drug interactions|Drug Interactions]]'''
| |
| '''| [[Tenecteplase use in specific populations|Use in Specific Populations]]'''
| |
| '''| [[Tenecteplase description|Description]]'''
| |
| '''| [[Tenecteplase clinical pharmacology|Clinical Pharmacology]]'''
| |
| '''| [[Tenecteplase nonclinical toxicology|Nonclinical Toxicology]]'''
| |
| '''| [[Tenecteplase clinical studies|Clinical Studies]]'''
| |
| '''| [[Tenecteplase how supplied storage and handling|How Supplied/Storage and Handling]]'''
| |
| '''| [[Tenecteplase labels and packages|Labels and Packages]]'''
| |
| | |
| ==Mechanism of Action==
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| {{Antithrombotics}}
| |
| | |
| [[Category:Thrombolytic drugs]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |